These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8961139)

  • 21. Orally active-targeted drug delivery systems for proteins and peptides.
    Li X; Yu M; Fan W; Gan Y; Hovgaard L; Yang M
    Expert Opin Drug Deliv; 2014 Sep; 11(9):1435-47. PubMed ID: 24962803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic.
    Maher S; Leonard TW; Jacobsen J; Brayden DJ
    Adv Drug Deliv Rev; 2009 Dec; 61(15):1427-49. PubMed ID: 19800376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral delivery of peptide therapeutics in infants: Challenges and opportunities.
    Gleeson JP; Fein KC; Whitehead KA
    Adv Drug Deliv Rev; 2021 Jun; 173():112-124. PubMed ID: 33774115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs.
    Wang J; Yadav V; Smart AL; Tajiri S; Basit AW
    Mol Pharm; 2015 Mar; 12(3):966-73. PubMed ID: 25612507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials.
    Aguirre TA; Teijeiro-Osorio D; Rosa M; Coulter IS; Alonso MJ; Brayden DJ
    Adv Drug Deliv Rev; 2016 Nov; 106(Pt B):223-241. PubMed ID: 26921819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concentration and surface of absorption: concepts and applications to gastrointestinal patches delivery.
    Teutonico D; Montanari S; Ponchel G
    Int J Pharm; 2011 Jul; 413(1-2):87-92. PubMed ID: 21536118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral drug delivery systems using chemical conjugates or physical complexes.
    Al-Hilal TA; Alam F; Byun Y
    Adv Drug Deliv Rev; 2013 Jun; 65(6):845-64. PubMed ID: 23220326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Approaches for enhancing oral bioavailability of peptides and proteins.
    Renukuntla J; Vadlapudi AD; Patel A; Boddu SH; Mitra AK
    Int J Pharm; 2013 Apr; 447(1-2):75-93. PubMed ID: 23428883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives.
    Pawar VK; Meher JG; Singh Y; Chaurasia M; Surendar Reddy B; Chourasia MK
    J Control Release; 2014 Dec; 196():168-83. PubMed ID: 25305562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs.
    van der Merwe SM; Verhoef JC; Verheijden JH; Kotzé AF; Junginger HE
    Eur J Pharm Biopharm; 2004 Sep; 58(2):225-35. PubMed ID: 15296951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzymatic barriers to peptide and protein absorption.
    Lee VH
    Crit Rev Ther Drug Carrier Syst; 1988; 5(2):69-97. PubMed ID: 3052875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Supersaturated polymeric micelles for oral cyclosporine A delivery.
    Yu H; Xia D; Zhu Q; Zhu C; Chen D; Gan Y
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1325-36. PubMed ID: 23954511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emulsion-based colloidal nanosystems for oral delivery of doxorubicin: improved intestinal paracellular absorption and alleviated cardiotoxicity.
    Kim JE; Yoon IS; Cho HJ; Kim DH; Choi YH; Kim DD
    Int J Pharm; 2014 Apr; 464(1-2):117-26. PubMed ID: 24463005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microemulsions for improved peptide absorption from the gastrointestinal tract.
    Ritschel WA
    Methods Find Exp Clin Pharmacol; 1991 Apr; 13(3):205-20. PubMed ID: 2051845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetically engineered normal flora for oral polypeptide delivery: dose-absorption response.
    Kaushal G; Shao J
    J Pharm Sci; 2009 Aug; 98(8):2573-80. PubMed ID: 19266563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel delivery systems for improving the clinical use of peptides.
    Kovalainen M; Mönkäre J; Riikonen J; Pesonen U; Vlasova M; Salonen J; Lehto VP; Järvinen K; Herzig KH
    Pharmacol Rev; 2015 Jul; 67(3):541-61. PubMed ID: 26023145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigating permeability related hurdles in oral delivery of 11-keto-β-boswellic acid.
    Bagul P; Khomane KS; Bansal AK
    Int J Pharm; 2014 Apr; 464(1-2):104-10. PubMed ID: 24463070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzymatic barriers for GI peptide and protein delivery.
    Woodley JF
    Crit Rev Ther Drug Carrier Syst; 1994; 11(2-3):61-95. PubMed ID: 7600588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Innovative strategies for the oral delivery of drugs and peptides.
    Fasano A
    Trends Biotechnol; 1998 Apr; 16(4):152-7. PubMed ID: 9586237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.